TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
|
|
- Allen Stafford
- 5 years ago
- Views:
Transcription
1 TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park Cancer Institute
2 CASE 53 y/o man T2N2cM0 Base of Tongue Cancer 40 pack years HPV positive Smokes 1.5 ppd Seen November 10 Because of work, wants to start on a wednesday Can t be changed
3 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
4 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
5 Treatment Time is Important with RT alone 1. Suwinski, R., et al., Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys, (2): p Robertson, A.G., et al., Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis. Radiother Oncol, (2): p Hliniak, A., B. Maciejewski, and K.R. Trott, The influence of the number of fractions, overall treatment time and field size on the local control of cancer of the skin. Br J Radiol, (668): p Maciejewski, B., et al., Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose response and repopulation. Int J Radiat Oncol Biol Phys, (3): p Robertson, C., et al., Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys, (2): p Kwong, D.L., et al., The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, (3): p
6 Tx Time & Hgb with ChemoRT Rades. IJROBP patients Stage IV Concurrent ChemoRT Definitive (70) or Post op (83)
7 Prognostic Factors Rades. IJROBP
8 Prognostic Factors Rades. IJROBP
9 Prognostic Factors Rades. IJROBP
10 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
11 Am Jn Clin Oncol
12 RPCI Study # patients Mostly male Oropharynx, larynx most common Treatment Chemotherapy AND IMRT # patients % Total 78 Median age (range) Sex 62 (37-81) Male 56 72% Female 22 28% Tumor Site Oropharynx 42 54% Larynx 28 36% Hypopharynx 4 5% Oral Cavity 4 5%
13 RPCI Study #1 H&N Cancers Mostly advanced 51% T3 or T4 55% N2 or N3 T Stage # % % % % % N Stage % % 2a 5 6% 2b 21 27% 2c 13 17% 3 4 5%
14 RPCI Study #1 Median follow up was 12 months. Fifteen of 78 (19%) patients experienced locoregional failure. 6 primary site failures, 5 nodal/ regional failures, and 4 failures in both the primary site and regional lymph nodes.
15 RPCI Study #1 Loco regional failure variables Age Sex Disease site Stage Baseline hemoglobin Treatment interruption > 1 week * Statistically significant meaning high level of correlation with loco-regional failures
16 RPCI Study #1 Low hemoglobin 7/19 (37%) failures Normal hemoglobin 8/59 (14%) failures P = 0.042
17 RPCI Study #1 Interruption > 1 week 6/13 (46%) failures Interruption < 1 week 9/65 (14%) failures P = 0.015
18 RPCI Study #1 : Summary More loco regional failures in H&N with Low hemoglobin Not easily / realistically correctable Treatment interruptions Easily Correctable! but will it matter?
19 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
20 Head and Neck
21 RPCI Study # patients Mostly male Oropharynx, larynx most common Treatment Chemotherapy AND IMRT Avoid treatment interruptions # patients % Total 62 Median age (range) Sex 59 (38-82) Male 51 82% Female 11 18% Tumor Site Oropharynx 37 66% Larynx 14 25% Hypopharynx 5 9% Oral Cavity 0 0%
22 Treatment Time at RPCI Median RT duration (days) (n = 78) 51 (39 83) (n = 62) 46 (38 67) Local Control 81 vs 95%, P=0.01 Duration < 56 days % Duration > 56 days %
23 Optimal Treatment Time Start on a Monday! Sun Mo Tu We Th Fr Sat Treatment time = 47 days Sun Mo Tu We Th Fr Sat Treatment time = 49 days Up to 6 fx/week if needed
24 IMRT Prescription Total dose 70 Gy 2 Gy per fraction 35 treatments. Treatment time 35 fractions (35 days) 6 weekends (12 days) Total time 47 days RPCI Study #2 Sun Mo Tu We Th Fr Sat
25 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
26 RTOG 0129 Post Hoc Analysis Retrospective Analysis Randomized Trial Stage III and IV Oropharyngeal cancer Accelerated fractionation vs Standard fractionation patients 323 patients had HPV status known. Ang KK, New England Journal of Medicine. 2010; 363, 24-35
27 RTOG 0129 Post Hoc Analysis Ang KK, New England Journal of Medicine. 2010; 363, 24-35
28 RTOG 0129 Post Hoc Analysis Ang KK, New England Journal of Medicine. 2010; 363, 24-35
29 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
30 Effect of Smoking on H&N Ca Retrospective Study patients All H&N disease sites All stages Follow up time approximately 3 years. Fortin et al. Int. J. Radiation Oncology Biol. Phys., Vol. 74, No. 4, pp , 2009
31 Effect of Smoking on H&N Ca Fortin et al. Int. J. Radiation Oncology Biol. Phys., Vol. 74, No. 4, pp , 2009
32 Effect of Smoking on H&N Ca Fortin et al. Int. J. Radiation Oncology Biol. Phys., Vol. 74, No. 4, pp , 2009
33 Smoking During RT Bad Outcome Chen. Int Jn Radiat Oncol Biol Phys Retrospective Study, case matched ( ) 202 patients Former smoker anyone who quit anytime prior to RT Squamous cell cancer of Oral cavity Pharynx (Naso, Oro, Hypo ) Larynx Median follow up 49 months
34 Smoking During RT Bad Outcome Overall Survival Chen et al. Int. J. Radiation Oncology Biol. Phys., Vol. 79, No. 2, pp , 2011
35 Smoking During RT Bad Outcome Loco-regional Control Chen et al. Int. J. Radiation Oncology Biol. Phys., Vol. 79, No. 2, pp , 2011
36 Smoking + RT = bad idea. Fortin (2009) 5 yr LRC Former Active 80% 67% 5 yr OS Former 55% Active 50% Chen (2011) 69% 58% 55% 23% Int Jn of Rad Onc Biol Phys
37 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
38 120 pts
39 HPV+ Never/Former p<0.01 HPV+ Active smoker HPV- Never/Former p<0.28 HPV- Active smoker 90% OS in those who quit 30 days prior to starting RT.
40 Outline TREATMENT TIME Historical Data RPCI Experience pt 1 3 4% per day over 50 RPCI Experience pt 2 Preventing treatment prolongation works TOBACCO It is bad for you Bad during RT Quitting prior to RT makes a BIG difference
41 CASE 53 y/o man T2N2cM0 Base of Tongue Cancer 40 pack years HPV positive Smokes 1.5 ppd Seen November 10 Because of work, wants to start on a wednesday Can t be changed
42 Smokes 1.5 ppd Seen November 10 CASE Smoking Cessation TX 6 fx/wk wknd/bid to cmplete in 47d Because of work, wants to start on a wednesday Start on a Monday
Pre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationTHE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER
THE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER Piotr Milecki 1, Grażyna Stryczyńska 1, Aleksandra Kruk-Zagajewska 2 Department of Radiotherapy,
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationHead and Neck Cancer: Altered Fractionation Schedules
Head and Neck Cancer: Altered Fractionation Schedules M.I. SAUNDERS Marie Curie Research Wing, Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom Key Words. Head and
More informationQuality Variation and Clinical Impact in Head and Neck IMRT
Quality Variation and Clinical Impact in Head and Neck IMRT 6 th IMRT Symposium, New York Sep. 20, 2010 K.S. Clifford Chao, MD Chairman, Combined Radiation Oncology, New York Presbyterian Hospital Chairman,
More informationMANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationPhysician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters
Physician to Physician Head and Neck William M. Lydiatt, MD Chair of Surgery Nebraska Methodist Hospital Clinical Professor of Surgery, Creighton University Validating science. Improving patient care.
More informationHPV POSITIVE OROPHARYNGEAL CARCINOMA the radiation oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV POSITIVE OROPHARYNGEAL CARCINOMA the radiation oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HEAD AND NECK CANCER -HPV Change in incidence: HEAD AND NECK
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.128 Research Paper Comparison of
More informationESMO Perceptorship H&N cancer Epidemiology, Anatomy and Workup 16 March 2018
ESMO Perceptorship H&N cancer Epidemiology, Anatomy and Workup 16 March 2018 Dr. Victor Ho-Fun Lee MBBS, MD, FRCR, FHKCR, FHKAM (Radiology) Clinical Associate Professor Department of Clinical Oncology
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationOral Cavity Cancer Combined modality therapy
Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no
More informationCompliance to Head and Neck Radiotherapy in Our Patient Population
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 4 Ver. VII (April. 2017), PP 48-52 www.iosrjournals.org Compliance to Head and Neck Radiotherapy
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationDiagnosis and what happens after referral
Diagnosis and what happens after referral Dr Kate Newbold Consultant in Clinical Oncology The Royal Marsden Women's cancers Breast cancer introduction 1 Treatment Modalities Early stage disease -larynx
More informationRADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationHPV-Related Head and Neck Squamous Cancers
2015 Wisconsin Comprehensive Cancer Control Summit Aligning Partners, Priorities, and the Plan HPV-Related Head and Neck Squamous Cancers MCW Department of Otolaryngology and Communication Sciences MCW
More informationPractice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE LIFE THROUGH MEDICAL MEDICAL EDUCATION EDUCATION www.excemed.org
More informationThe PreciseART Approach to Adaptive Radiotherapy with the RADIXACT System. Prof. Anne Laprie Radiation Oncologist
The PreciseART Approach to Adaptive Radiotherapy with the RADIXACT System Prof. Anne Laprie Radiation Oncologist Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation The views
More informationSquamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations
Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Troy G. Scroggins Jr. MD Chairman, Department of Radiation Oncology Ochsner Health Systems 1 Association of Postoperative Radiotherapy
More informationImpact of Anemia in Patients With Head and Neck Cancer
Impact of Anemia in Patients With Head and Neck Cancer PARVESH KUMAR Department of Radiation Oncology, UMDNJ/Robert Wood Johnson Medical School, Cancer Institute of New Jersey, St. Peter s University Hospital,
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationPRINCIPLES OF RADIATION ONCOLOGY
PRINCIPLES OF RADIATION ONCOLOGY Ravi Pachigolla, MD Faculty Advisor: Anna Pou, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation January 5, 2000 HISTORY
More informationHead and Neck cancer
Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction
More informationRadiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer Gregory Russo, Robert Haddad, Marshall Posner and Mitchell Machtay
Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer Gregory Russo, Robert Haddad, Marshall Posner and Mitchell Machtay The Oncologist published online August 13, 2008 The online
More informationHALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy
The Physical and Biological Basis of By 1899 X rays were being used for cancer therapy David J. Brenner, PhD, DSc Center for Radiological Research Department of Radiation Oncology Columbia University Medical
More informationComparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers
Original Research Article Comparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers Kuppa Prakash 1*, A. Ravi Chandran 2, M.
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationHead & Neck Cancer: When to Irradiate
Head & Neck Cancer: When to Irradiate ESO-ESMO Latin-America 2018 Talented students colleagues 1 > 15 different diseases for RT strategies NC NP OC OP H L 2 HPV Prognostic Marker >2010 Trial Cases Marker
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationRANDOMIZED TRIAL ADDRESSING RISK FEATURES AND TIME FACTORS OF SURGERY PLUS RADIOTHERAPY IN ADVANCED HEAD-AND-NECK CANCER
PII S0360-3016(01)01690-X Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 3, pp. 571 578, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationOral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
More informationHead and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.
Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationFirst of all, the pathophysiology
Welcome. My name is Eric Sturgis and I m a Professor in Head and Neck Surgery with a joint appointment in the Department of Epidemiology at The University of Texas MD Anderson Cancer Center. And today
More informationHead and Neck Cancer Service
Dr Hoda Al Booz. MMedSci, MD, FFRRCSI, FRCR. Head and Neck Cancer Service Dr Hoda Al Booz Consultant in Clinical Oncology Bristol Cancer Institute Dr Hoda Al Booz. MMedSci, MD, FFRRCSI, FRCR. documents/
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationESRA KAYTAN SAĞLAM, MD Istanbul University Oncology Institute
USE OF RADIOSENSITIZERS IN ONCOLOGY ESRA KAYTAN SAĞLAM, MD Istanbul University Oncology Institute According to cell type: Radiosensitive tumors (embryojenic tumors, lymphomas) Moderate sensitives (Squamous
More informationOutcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21 st century
Garden et al. Radiation Oncology 2013, 8:21 RESEARCH Open Access Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21 st century Adam S Garden
More informationREIRRADIATION OF HEAD & NECK TARGETS
REIRRADIATION OF HEAD & NECK TARGETS WORKSHOP-Current challenges of patient re-irradiation 6-7 september 2018, Stockholm, Sweden Claes Mercke Karolinska Institute and Karolinska University Hospital STOCKHOLM
More informationComparison of acute toxicities of two chemotherapy schedules for head and neck cancers
Original Article Free full text available from www.cancerjournal.net Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers Geeta SN, TK Padmanabhan, J Samuel, K Pavithran*,
More informationHuman Papillomavirus in Head and Neck Cancer
Human Papillomavirus in Head and Neck Cancer Adam L. Holtzman, M.D. ACLI Medical Section Meeting 2019 Disclosures Employment Relationship University of Florida Compensation, Remuneration, Funding None
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationRadio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology
Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology March 2018 > Half million new cases HNC/year in world 50-60% cured not cured
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationDifferent Factors May Affect Clinical Outcome of Early Laryngeal Cancer
Med. J. Cairo Univ., Vol. 81, No. 2, December: 121-126, 2013 www.medicaljournalofcairouniversity.net Different Factors May Affect Clinical Outcome of Early Laryngeal Cancer SEHAM E. ABDELKHALEK, M.D. The
More informationResponse Evaluation Of Accelerated Fractionation With Concomitant Boost Chemoradiation In Locally Advanced Squamous Cell Head And Neck Cancer
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. IV (Feb. 2016), PP 27-32 www.iosrjournals.org Response Evaluation Of Accelerated Fractionation
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationUSING LOW DOSE RADIATION TO POTENTIATE INDUCTION CHEMOTHER APY IN THE MANAGE- MENT OF LOCALLY ADVANCED HEAD AND NECK MALIGNANCY.
ORIGINAL ARTICLE - RADIATION ONCOLOGY USING LOW DOSE RADIATION TO POTENTIATE INDUCTION CHEMOTHER APY IN THE MANAGE- MENT OF LOCALLY ADVANCED HEAD AND NECK MALIGNANCY C.Sundaresan (1), P.K.Baskar (2), V.Sanjal
More informationRT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
More informationClinical Case Conference Melanoma
Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation
More informationYuzuru Niibe 1, Katsuyuki Karasawa 1, Toshio Mitsuhashi 2 and Yoshiaki Tanaka 3 INTRODUCTION. Jpn J Clin Oncol 2003;33(9)
Jpn J Clin Oncol 2003;33(9)450 455 Hyperfractionated Radiation Therapy for Hypopharyngeal Carcinoma Compared with Conventional Radiation Therapy: Local Control, Laryngeal Preservation and Overall Survival
More informationCase Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma
Case Scenario 1 History A 52 year old male with a 20 pack year smoking history presented with about a 6 month history of persistent hoarseness. The patient had a squamous cell carcinoma of the lip removed
More informationManagement of unknown primary with neck node metastasis: Current evidence
Management of unknown primary with neck node metastasis: Current evidence Dr. Pooja Nandwani Patel Associate Professor Dept. of Radiation Oncology GCRI, Ahmedabad Introduction- Approach to Topic What is
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationScottish Audit of Head and Neck Cancers. A Prospective Audit
Scottish Audit of Head and Neck Cancers Steering Group Scottish Audit of Head and Neck Cancers A Prospective Audit Report 1999 2002 Edited by David Loeb and Tracey Rapson Statistical Analysis by Tracey
More informationComparing Alternative treatment Regimens for intermediate and high risk oropharyngeal cancer CompARE. Prof. Hisham Mehanna.
Comparing Alternative treatment Regimens for intermediate and high risk oropharyngeal cancer CompARE Prof. Hisham Mehanna Chief investigator: Hisham Mehanna Arm 1: Mehmet Sen Arm2: John Chester/Martin
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationNasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar)
Nasopharynx Cancer 1 Feb 2016 Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Expert Panels Prof Mo Mo Tin Prof Michael Boyer Dr Raewyn Campbell Prof
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More information3/12/2018. Head & Neck Cancer Review INTRODUCTION
Head & Neck Cancer Review Joseph Rosales, MD March 12, 2018 INTRODUCTION Epidemiology/Risk Factors Anatomy Presentation/Workup Treatment Surgery vs Radiation Chemotherapy Side effects Special circumstances
More informationTOPICS. Primary Radiation Therapy. Targeted Therapy in Oncology. Principles of Radiation Therapy. Principles of Radiation Therapy
Peter B. Schiff, M.D., Ph.D. Department of Radiation Oncology Columbia University College of Physicians & Surgeons May 4, 2007 Targeted Therapy in Oncology Surgical Oncology Minimal invasive techniques
More informationCOMPAR ATIVE STUDY ON CONVENTIONAL VERSUS HYPOFR ACTIONATED R ADIOTHER APY IN LOCALLY ADVANCED HEAD AND NECK CANCER. Abstract
ORIGINAL ARTICLE - RADIATION ONCOLOGY COMPAR ATIVE STUDY ON CONVENTIONAL VERSUS HYPOFR ACTIONATED R ADIOTHER APY IN LOCALLY ADVANCED HEAD AND NECK CANCER. Poonkodi.N (1), P K Baskar (1), Praveengeeth (1)
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationACR Appropriateness Criteria Adjuvant Therapy for Resected Squamous Cell Carcinoma of the Head and Neck EVIDENCE TABLE
1. Johnson JT, Barnes EL, Myers EN, Schramm VL, Jr., Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 1981; 107(1):75-79.. Snow GB, Annyas AA,
More informationNearly 60% of all cancers currently are diagnosed in patients age
648 Feasibility and Early Results of Accelerated Radiotherapy for Head and Neck Carcinoma in the Elderly Abdelkarim S. Allal, M.D. 1 Daphné Maire, M.D. 1 Minerva Becker, M.D. 2 Pavel Dulguerov, M.D. 3
More informationPrinciples of Management of Head & Neck Cancer. Jinka Sathya Associate professor of Oncology
Principles of Management of Head & Neck Cancer Jinka Sathya Associate professor of Oncology Oral cavity Oro-pharynx Larynx Hypopharynx Nasophaynx Major sites of Mucosal H&N Cancers Head & Neck Cancer Oral
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationEvaluation and Management of Head and Neck Cancer in Patients with Fanconi anemia David I. Kutler, M.D., F.A.C.S.
Evaluation and Management of Head and Neck Cancer in Patients with Fanconi anemia David I. Kutler, M.D., F.A.C.S. Residency Site Director Weill Cornell Medical Center Associate Professor Division of Head
More informationJMSCR Vol 04 Issue 11 Page November 2016
www.jmscr.igmpublication.org Impact Factor 5.44 Index Copernicus Value: 83.7 ISSN (e)-347-76x ISSN (p) 455-0450 DOI: https://dx.doi.org/0.8535/jmscr/v4i.90 Accelerated Fractionation Radiotherapy in Head
More informationMultimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Amanda Psyrri, MD,FACP Attikon University Hospital Athens, Greece Learning objectives After reading and reviewing this material,
More informationCancer Medicine. Introduction. Open Access ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationFrom GTV to CTV: A Critical Step Towards Cure. Kenneth Hu, MD Associate Professor New York University Langone Medical Center June 21, 2017
From GTV to CTV: A Critical Step Towards Cure Kenneth Hu, MD Associate Professor New York University Langone Medical Center June 21, 2017 Head and Neck Cancer Model for Understanding CTV Expansion Radiation
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationConcurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Original article Annals of Oncology 14: 1306 1311, 2003 DOI: 10.1093/annonc/mdg330 Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary A. Argiris
More informationClinical Discussion. Dr Pankaj Chaturvedi. Professor and Surgeon Tata Memorial Hospital
Clinical Discussion Dr Pankaj Chaturvedi Professor and Surgeon Tata Memorial Hospital chaturvedi.pankaj@gmail.com 47/M/smoker Hopkins : Transglottic lesion No cartilage infiltration but sclerosis Left
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationQUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
More informationHead and Neck Service
Head and Neck Service University of California, San Francisco, Department of Radiation Oncology Residency Training Program Head and Neck and Thoracic Service Educational Objectives for PGY-5 Residents
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationFDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma This article discusses the value of 18F-fluoro-2-deoxyglucose PET/CT imaging biomarkers in head and neck squamous cell carcinoma.
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationProtons for Head and Neck Cancer. William M Mendenhall, M.D.
Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major
More information